Firm News

The Latest News from Lucosky Brookman

Lucosky Brookman is a leader in the representation of small and micro-cap companies. The Firm has led it clients through numerous capital raise transaction and over a dozen uplisting and initial public offering transactions.  Access the latest news about Lucosky Brookman, our clients’ business transactions and industry updates here. 

Lucosky Brookman Successfully Represents BiondVax Pharmaceuticals Ltd. in Closing of $9.8 million Follow-on Underwritten Offering of ADSs

Lucosky Brookman LLP congratulates its client, BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) on its successful closing of an underwritten public offering of 4,144,068 American Depositary Shares ("ADSs") at a public offering price of $2.36 per ADS for gross proceeds to the Company of approximately $9.8 million. BiondVax Pharmaceuticals Ltd. is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses.

Lucosky Brookman acted as corporate and securities counsel to the Company while Aegis Capital Corp. acted as sole book-running manager for the offering.

BiondVax Pharmaceuticals Ltd.  intends to use the net proceeds from this offering for the advancement of its recently announced nanosized antibody (NanoAb) development program as well as for general corporate purposes. It may also use a portion of the net proceeds to in-license, invest in or acquire businesses, assets or technologies that it believes are complementary to its business focus, although it has no current commitments or agreements in those regards.